IRVAN syndrome: A case report and a literature review

Mansour, Marah; Al-Ghotani, Basel; Abo-Shdeed, Bana; Jannoud, Omaya

doi:10.1016/j.amsu.2022.103725

Cited by 3 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in concordance with those of the study of Mansour et al, in which management with intravitreal injections of aflibercept plus heavy PRP was associated with a lower rate of treatment failure compared to management with a single treatment [6]. Similarly, this form of management resulted in the resolution of retinal aneurysms and leakage, as well as a significant reduction of CME.…”

Section: Discussionsupporting

confidence: 91%

“…Retinal vasculitis, aneurysmal dilations, and neuroretinitis are the three primary criteria of IRVAN, while peripheral capillary nonperfusion, retinal neovascularization, and macular exudation comprise the minor criteria [2]. A literature review of IRVAN found that blurred vision and vision loss are the most common symptoms at presentation [6]. There are two main characteristics of IRVAN syndrome, i.e., exudative retinopathy and peripheral capillary nonperfusion, that pose the greatest risk to vision [6].…”

Section: Discussionmentioning

confidence: 99%

“…A literature review of IRVAN found that blurred vision and vision loss are the most common symptoms at presentation [6]. There are two main characteristics of IRVAN syndrome, i.e., exudative retinopathy and peripheral capillary nonperfusion, that pose the greatest risk to vision [6].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, the standard treatment of PRP was administered to curtail the metabolic demand of the areas of ischemia in the retina since various articles advised the use of PRP to prevent neovascularization and resolve retinal aneurysms and leaks [6,[17][18][19]. Therefore, to minimize the inflammation provoked by the procedure, the patient's treatment with PRP took place in a fragmented fashion.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Aflibercept for the Treatment of Macular Edema Secondary to Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome

Fontanet¹,

Rodríguez²,

Oliver³

2023

Cureus

View full text Add to dashboard Cite

We report a case of idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome in a patient whose cystoid macular edema (CME) was successfully treated with aflibercept and pan-retinal photocoagulation (PRP). A 56-year-old male was sent to our uveitis service for further evaluation after a fluorescein angiogram revealed symmetric retinal ischemia for 360 degrees in both eyes. A fundus examination revealed an aneurysm, neuroretinitis, and occlusive vasculitis, all consistent with a diagnosis of IRVAN syndrome. An optical coherence tomography examination revealed CME of the left eye. A chest X-ray revealed minimally prominent interstitial markings. The patient had a positive QuantiFERON-TB Gold test and was treated for tuberculosis with a one-year course of isoniazid and pyrimethamine. A further workup for other infectious and autoimmune etiologies was negative. The initial treatment consisted of bilateral PRP of the areas of peripheral ischemia, treatment for which was provided in a fragmented fashion over the course of seven months. Soon after the diagnosis, he received treatment with two intravitreal injections of aflibercept (2 mg/0.5 mL), one month apart, to the left eye. Subsequently, four months following the presentation, he developed CME in the right eye, which was treated with a single intravitreal injection of aflibercept (2 mg/0.5 mL). At his last follow-up visit, four years after the initial presentation, the patient remained asymptomatic with 20/20 visual acuity in both eyes and no evidence of CME recurrence. Our case suggests that aflibercept may serve as an adjuvant to the standard treatment with PRP, especially in cases that present with associated macular edema.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Aflibercept for the Treatment of Macular Edema Secondary to Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome

Fontanet¹,

Rodríguez²,

Oliver³

2023

Cureus

View full text Add to dashboard Cite

show abstract

Aflibercept/bevacizumab/infliximab

2022

Reactions Weekly

View full text Add to dashboard Cite

Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders

Sota,

Guerriero,

Lopalco

et al. 2024

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

Introduction: Since many biological drug patents have expired, biosimilar agents (BIOs) have been developed; however, there are still some reservations in their use, especially in childhood. The aim of the current study is to evaluate the efficacy and safety of tumor necrosis factor (TNF) inhibitors BIOs as treatment for pediatric non-infectious uveitis (NIU). Methods: Data from pediatric patients with NIU treated with TNF inhibitors BIOs were drawn from the international AutoInflammatory Disease Alliance (AIDA) registries dedicated Maria Tarsia and Antonio Vitale contributed equally.

show abstract

IRVAN syndrome: A case report and a literature review

Cited by 3 publications

References 19 publications

Aflibercept for the Treatment of Macular Edema Secondary to Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome

Aflibercept for the Treatment of Macular Edema Secondary to Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome

Aflibercept/bevacizumab/infliximab

Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders

Contact Info

Product

Resources

About